TP53 and lung carcinoma: In lung cancer, the F395C mutation was identified to disrupt the B56γ-p53 interaction, leading to the failure in the p53-dependent tumor-suppressive function of PP2A by inhibiting p53 Thr55 dephosphorylation and p21 transcription [69].